CAUTION: Federal law restricts this device to sale by or on the order of a physician trained or experienced in device implant and follow-up procedures.
TABLE OF CONTENTS

DESCRIPTION .................................................................................................................. 1
MR Conditional Pacing System Information ................................................................. 1
Lead Implant-related MRI Conditions of Use............................................................. 1
Lead Features............................................................................................................. 1
RELATED INFORMATION............................................................................................ 1
Intended Audience ................................................................................................. 1
INDICATIONS ................................................................................................................. 2
CONTRAINDICATIONS ............................................................................................... 2
WARNINGS .................................................................................................................... 2
PRECAUTIONS ............................................................................................................ 2
General ....................................................................................................................... 2
Handling ..................................................................................................................... 3
Implanting .................................................................................................................. 3
POTENTIAL ADVERSE EVENTS ................................................................................. 3
WARRANTY .................................................................................................................. 4
ADVERSE EVENTS ...................................................................................................... 4
CLINICAL SUMMARY: ................................................................................................. 5
Objectives .................................................................................................................. 6
Methods ...................................................................................................................... 6
Results ......................................................................................................................... 6
IMPLANT INFORMATION ............................................................................................ 6
Precautions ................................................................................................................ 7
Sterilization ................................................................................................................ 7
Storage ......................................................................................................................... 7
Handling ..................................................................................................................... 7
Precautions ................................................................................................................. 7
General Information ................................................................................................. 7
Precautions ................................................................................................................ 7
Insertion Procedures ................................................................................................. 7
Atrial Placement ........................................................................................................ 7
Ventricular Placement ............................................................................................... 8
Threshold Measurements .......................................................................................... 8
Ventricular .................................................................................................................. 8
Atrial ........................................................................................................................... 8
Securing the Lead ...................................................................................................... 8
POSTIMPLANT ............................................................................................................. 10
RETURNING EXPLANTED PRODUCTS ..................................................................... 10
SYMBOLS ON PACKAGING ..................................................................................... 11
SPECIFICATIONS ....................................................................................................... 12
DESCRIPTION
The FINELINE™ II Sterox models 4456, 4457, 4458, 4459, 4479, and 4480 bipolar endocardial pacing leads are designed for atrial or ventricular use with implantable pulse generators for long-term cardiac pacing.

⚠️ MR Conditional System Information
These leads can be used as part of the ImageReady™ MR Conditional Pacing System or the ImageReady MR Conditional Defibrillation System (hereafter each referred to as an MR Conditional System) when connected to Boston Scientific ImageReady MR Conditional pulse generators. Patients with an MR Conditional System may be eligible to undergo MRI scans if performed when all Conditions of Use, as defined in the ImageReady MR Conditional Pacing System MRI Technical Guide or the ImageReady MR Conditional Defibrillation System MRI Technical Guide¹ (hereafter each referred to as the MRI Technical Guide), are met. Components required for MR Conditional status include specific models of Boston Scientific pulse generators, leads, and accessories; the Programmer/Recorder/Monitor (PRM); and PRM Software Application. For the model numbers of MR Conditional pulse generators and components, as well as a complete description of the ImageReady MR Conditional System, refer to the applicable MRI Technical Guide.

⚠️ Implant-related MRI Conditions of Use
The following subset of the MRI Conditions of Use pertains to implantation, and is included as a guide to ensure implantation of a complete ImageReady MR Conditional System. For a full list of Conditions of Use, refer to the applicable MRI Technical Guide. All items on the full list of Conditions of Use must be met in order for an MRI scan to be considered MR Conditional.

- Patient is implanted with the ImageReady MR Conditional Pacing System² or the ImageReady MR Conditional Defibrillation System³
- No other active or abandoned implanted devices, components, or accessories present such as lead adaptors, extenders, leads or pulse generators
- Bipolar pacing operation or pacing off with the ImageReady MR Conditional Pacing System
- Pulse generator implant location restricted to left or right pectoral region
- At least six (6) weeks have elapsed since implantation and/or any lead revision or surgical modification of the MR Conditional System
- Pacing threshold $\leq 2.0 \text{ V}$ in pace-dependent patients with the ImageReady MR Conditional Pacing System
- No evidence of a fractured lead or compromised pulse generator-lead system integrity

Lead Features
A silicone rubber collar at the distal tip contains 0.75 mg of dexamethasone acetate. Each lead is composed of two individually coated conductor wires coradially wound together to form a single conductor coil. The lead includes silicone rubber (models 4458 and 4459) or polyurethane (models 4456, 4457, 4479, and 4480) outer insulation, iridium oxide-coated (IROX™) titanium tip electrode and a platinum iridium anode. The distal slotted/blunt tip electrode is coated with polyethylene glycol. Fixation is achieved by silicone rubber tines. The lead is compatible with pulse generators having IS-1⁴ connectors.

Pacing and sensing impedance values, determined according to European Standard EN 45502-2-1:2003 (paragraphs 6.2.2 and 6.2.3), are within 780-1125 $\Omega$ and 595-790 $\Omega$, respectively. Note that these values are derived from in vitro testing, and are not representative of clinically measured lead impedance.

This device is intended for single-use only.

---

¹. Available at www.bostonscientific-elabeling.com.
². Defined as a Boston Scientific MR Conditional pulse generator and lead(s), with all ports occupied by a lead or port plug.
³. Defined as a Boston Scientific MR Conditional pulse generator and lead(s), with all ports occupied by a lead or port plug.
⁴. IS-1 refers to the international standard ISO 5841-3:2013.
RELATED INFORMATION
For additional information, go to www.bostonscientific-elabeling.com.

Intended Audience
This literature is intended for use by professionals trained or experienced in device implant and/or follow-up procedures.

INDICATIONS
The lead is intended for chronic pacing and sensing of the ventricle (4456, 4457, 4458, 4459) or the atrium (4479, 4480) when used with a compatible pulse generator.

CONTRAINDICATIONS
Do not use this lead in patients with:

- mechanical tricuspid heart valves
- hypersensitivity to a maximum single dose of 0.94 mg dexamethasone acetate

WARNINGS

NOTE: Refer to the applicable MRI Technical Guide for a complete list of MRI-related Warnings and Precautions.

- Unless all of the MRI Conditions of Use (as described in the MRI Technical Guide) are met, MRI scanning of the patient does not meet MR Conditional requirements for the implanted system, and significant harm to or death of the patient and/or damage to the implanted system may result. Refer to the MRI Technical Guide for potential adverse events applicable when Conditions of Use are met or not met, as well as for a complete list of MRI-related Warnings and Precautions.

- Implant of the system cannot be performed in an MRI site Zone III (and higher) as defined by the American College of Radiology Guidance Document for Safe MR Practices. Some of the accessories packaged with pulse generators and leads, including the torque wrench and stylet wires, are not MR Conditional and should not be brought into the MRI scanner room, the control room, or the MRI site Zone III or IV areas.

- The use of battery-powered equipment is recommended during lead implantation and testing to protect against fibrillation that may be caused by alternating currents.

- Line-powered equipment used in the vicinity of the patient must be properly grounded.

- Lead connector pins must be insulated from any leakage currents that may arise from line-powered equipment.

- Diathermy exposure. Do not subject a patient with an implanted pulse generator and/or lead to diathermy since diathermy may cause fibrillation, burning of the myocardium, and irreversible damage to the pulse generator because of induced currents.

- For single patient use only. Do not reuse, reprocess, or resterilize. Reuse, reprocessing, or resterilization may compromise the structural integrity of the device and/or lead to device failure which, in turn, may result in patient injury, illness, or death. Reuse, reprocessing, or resterilization may also create a risk of contamination of the device and/or cause patient infection or cross-infection, including, but not limited to, the transmission of infectious disease(s) from one patient to another. Contamination of the device may lead to injury, illness, or death of the patient.

PRECAUTIONS

General

NOTE: Use of Boston Scientific MR Conditional pulse generators and leads is required for an implanted system to be considered MR Conditional. Refer to the appropriate ImageReady MR Conditional Pacing System or Defibrillation System MRI Technical Guide for model numbers of pulse generators, leads, accessories, and other system components needed to satisfy the Conditions of Use for MR Conditional scanning.

NOTE: Other implanted devices or patient conditions may cause a patient to be ineligible for an MRI scan, independent of the status of the patient’s ImageReady MR Conditional System.

• Inspect sterile packaging prior to opening. Do not use if damaged. (See “Sterilization” on page 7.)
• Prior to the implantation of this lead, confirm lead/pulse generator compatibility by contacting Boston Scientific using the information on the back cover.
• Defibrillating equipment should be kept nearby for immediate use during the implantation procedure.
• It has not been determined whether the warnings, precautions, or complications usually associated with injectable dexamethasone acetate apply to the use of this lead. Refer to the current Physicians’ Desk Reference™ for potential adverse effects.

Handling

• Avoid the use of excessive force or surgical instruments, as damage to the insulation could cause leakage and/or prevent proper lead function.
• Do not wipe or immerse the electrode in fluid.
• Use the suture sleeve when securing the lead to avoid placing the lead under extreme tension.
• Avoid bending the coil conductor, since attempts to restore the original shape may weaken the structure.

Implanting

• The subclavian venipuncture technique for lead introduction may be associated with an increased risk of conductor failure due to compressive forces generated in the medial angle between the clavicle and the first rib; thus, an extremely medial introduction site should be avoided.
• Remove the stylet and stylet guide/cap before connecting the lead to the pulse generator. Leaving the stylet in the lead could cause coil fracture and/or heart perforation.
• Do not suture directly to the insulation. Always use the suture sleeve to anchor the lead.

POTENTIAL ADVERSE EVENTS

Based on the literature and on pulse generator and/or lead implant experience, the following list includes the possible adverse events associated with implantation of products described in this literature:

• Air embolism
• Allergic reaction
• Arterial damage with subsequent stenosis
• Bleeding
• Bradycardia
• Breakage/failure of the implant instruments
• Cardiac perforation
• Cardiac tamponade
• Chronic nerve damage
• Component failure
• Conductor coil fracture
• Death
• Electrolyte imbalance/dehydration

6. Physicians’ Desk Reference is a trademark of Thomson Healthcare Inc.
• Elevated thresholds
• Erosion
• Excessive fibrotic tissue growth
• Extracardiac stimulation (muscle/nerve stimulation)
• Fluid accumulation
• Foreign body rejection phenomena
• Formation of hematomas or seromas
• Heart block
• Hemorrhage
• Hemothorax
• Inability to pace
• Inappropriate therapy (e.g., shocks and antitachycardia pacing [ATP] where applicable, pacing)
• Incisional pain
• Incomplete lead connection with pulse generator
• Infection including endocarditis
• Lead dislodgement
• Lead fracture
• Lead insulation breakage or abrasion
• Lead tip deformation and/or breakage
• Malignancy or skin burn due to fluoroscopic radiation
• Myocardial trauma (e.g., tissue damage, valve damage)
• Myopotential sensing
• Oversensing/undersensing
• Pericardial rub, effusion
• Pneumothorax
• Pulse generator and/or lead migration
• Syncope
• Tachyarrhythmias, which include acceleration or arrhythmias and early, recurrent atrial fibrillation
• Thrombosis/thromboemboli
• Valve damage
• Vasovagal response
• Venous occlusion
• Venous trauma (e.g., perforation, dissection, erosion)

⚠ For a list of Potential Adverse Events associated with MRI scanning, refer to the appropriate ImageReady MR Conditional Pacing System or Defibrillation System MRI Technical Guide.

WARRANTY
A limited warranty certificate for the lead is available. For a copy, contact Boston Scientific using the information on the back cover.

ADVERSE EVENTS
NOTE:
• Clinical investigation was conducted on the Intermedics models 430-35S, 430-25S, 432-35S leads, which are identical to the FINELINE II models 4456/4457, 4458/4459, 4479/4480 leads, respectively.
• In clinical application, dexamethasone sodium phosphate is functionally equivalent to dexamethasone acetate. The dexamethasone sodium phosphate collar was used in the clinical investigation.

The ThinLine II Sterox clinical investigation, as of April 14, 2000, involved 461 devices implanted in 238 patients (mean implant duration was 7.5 months, range 0.1 to 12.5 months). There were 30 observations and 6 complications reported during the study (see Table 1, Table 2, Table 3, and Table 4).

Thirteen deaths were reported during the clinical investigation; none were related to the lead.
The only difference between the ThinLine II Sterox silicone and ThinLine II Sterox polyurethane leads is the insulation material. Because of this, the safety and effectiveness profile for the ThinLine II Sterox silicone leads is expected to be similar to that of the ThinLine II Sterox polyurethane leads that were studied clinically. Therefore, the data presented on the ThinLine II Sterox polyurethane leads can be applied to the silicone version of the ThinLine II Sterox leads.

Table 1. Adverse events for the ThinLine II Sterox clinical study (Model 430-35S ventricle)

<table>
<thead>
<tr>
<th># of Patients (n=115)</th>
<th>% of Patients (95% CI)</th>
<th># of Leads*</th>
</tr>
</thead>
<tbody>
<tr>
<td>OBSERVATIONS (total)b</td>
<td>1</td>
<td>0.9 [0.0, 4.0]</td>
</tr>
<tr>
<td>Suture sleeve, probable fracture</td>
<td>1</td>
<td>0.9 [0.0, 4.0]</td>
</tr>
<tr>
<td>COMPLICATIONS (total)c</td>
<td>1</td>
<td>0.9 [0.0, 4.0]</td>
</tr>
<tr>
<td>Lead dislodgement - ventricle</td>
<td>1</td>
<td>0.9 [0.0, 4.0]</td>
</tr>
</tbody>
</table>

Patients and leads may have multiple AEs.

Table 2. Adverse events for the ThinLine II Sterox clinical study (Model 432-35S)

<table>
<thead>
<tr>
<th># of Patients (n=37)</th>
<th>% of Patients (95% CI)</th>
<th># of Leads*</th>
</tr>
</thead>
<tbody>
<tr>
<td>OBSERVATIONS (total)b</td>
<td>2</td>
<td>5.4 [0.9, 18.1]</td>
</tr>
<tr>
<td>Opened by mistake.</td>
<td>1</td>
<td>2.7 [0.1, 14.1]</td>
</tr>
<tr>
<td>Placement difficulty, difficulty positioning.</td>
<td>1</td>
<td>2.7 [0.1, 14.1]</td>
</tr>
<tr>
<td>COMPLICATIONS (total)c</td>
<td>0</td>
<td>NA</td>
</tr>
</tbody>
</table>

Patients and leads may have multiple AEs.

Table 3. Adverse events for the ThinLine II Sterox clinical study (Model 438-35S atrium)

<table>
<thead>
<tr>
<th># of Patients (n=169)</th>
<th>% of Patients (95% CI)</th>
<th># of Leads*</th>
</tr>
</thead>
<tbody>
<tr>
<td>OBSERVATIONS (total)b</td>
<td>17</td>
<td>10.1 [6.1, 15.7]</td>
</tr>
<tr>
<td>Attempted, not used</td>
<td>1</td>
<td>0.6 [0.0, 3.3]</td>
</tr>
<tr>
<td>Brady capture - none or loss</td>
<td>1</td>
<td>0.6 [0.0, 3.3]</td>
</tr>
<tr>
<td>Oversensing - atrium pace</td>
<td>2</td>
<td>1.2 [0.2, 4.3]</td>
</tr>
<tr>
<td>PEG capsule came off</td>
<td>13</td>
<td>7.7, 4.3, 12.9</td>
</tr>
<tr>
<td>Undersensing - atrium pace</td>
<td>1</td>
<td>0.6, [0.0, 3.3]</td>
</tr>
<tr>
<td>COMPLICATIONS (total)c</td>
<td>1</td>
<td>0.6 [0.0, 3.3]</td>
</tr>
<tr>
<td>Lead Dislodgement - Right</td>
<td>1</td>
<td>0.6 [0.0, 3.3]</td>
</tr>
</tbody>
</table>

Patients and leads may have multiple AEs.

Table 4. Adverse events for the ThinLine II Sterox clinical study (Model 438-35S ventricle)

<table>
<thead>
<tr>
<th># of Patients (n=118)</th>
<th>% of Patients (95% CI)</th>
<th># of Leads*</th>
</tr>
</thead>
<tbody>
<tr>
<td>OBSERVATIONS (total)b</td>
<td>8</td>
<td>6.8 [3.2, 13.1]</td>
</tr>
<tr>
<td>Helix related (screw tip)</td>
<td>1</td>
<td>0.8 [0.0, 4.7]</td>
</tr>
<tr>
<td>PEG capsule came off</td>
<td>7</td>
<td>5.9, [2.6, 12.0]</td>
</tr>
<tr>
<td>COMPLICATIONS (total)c</td>
<td>2</td>
<td>1.7 [0.3, 6.1]</td>
</tr>
<tr>
<td>Diaphragmatic stimulation</td>
<td>1</td>
<td>0.8 [0.0, 4.7]</td>
</tr>
<tr>
<td>Placement difficulty, difficulty positioning</td>
<td>1</td>
<td>0.8 [0.0, 4.7]</td>
</tr>
</tbody>
</table>

Patients and leads may have multiple AEs.

*The number of leads is also the number of adverse events (lead and non-lead related) as there were no patients who had the same event multiple times.

*Observations are defined as symptomatic or asymptomatic clinical events with potential adverse effects which do not require surgical intervention (can be corrected by reprogramming alone).

*Complications are defined as symptomatic or asymptomatic clinical events with potential adverse effects which require surgical intervention. Explants are included as complications.

*Electrical performance of Model 430-25S and 438-25S is supported by the ThinLine II Sterox clinical data.
CLINICAL SUMMARY:
The Polyurethane ThinLine II Sterox pacing lead models 430-35S, 432-35S, and 438-35S were evaluated in a multi-center study with a randomized control comparison and a comparison to a historical control lead. The commercially available control leads in the randomized study were ThinLine I model 432-04 (atrial), 430-10 (ventricular) and 438-10 (atrial/ventricular). As of April 13, 2000, the investigation involved 461 devices implanted in 238 patients.

Objectives
• To demonstrate the effectiveness of the Polyurethane ThinLine II Sterox model 430-35S, 432-35S and 438-35S pacing lead by comparing pacing thresholds to a randomized commercially available control lead (model 430-10, 432-04, and 438-10).
• To demonstrate the effectiveness of the Polyurethane ThinLine II Sterox model 430-35S by comparing pacing thresholds to a commercially available steroid-eluting passive fixation lead.
• To demonstrate the safety of the lead by establishing the comparability of the incidence rate of device-related observations and complications to that of the control lead.

Methods
Follow-ups to collect electrical performance data occurred at 2 weeks, 4 weeks, 6 weeks, and three months. Safety data was taken from all reported information.

Table 5. Mean Pulse Width Threshold at 2.5 V (Objective 1. Pooled Data from all Test Leads*: Models 430-35S, 432-35S and 438-35S)

<table>
<thead>
<tr>
<th>Follow-up</th>
<th>Randomized Leads</th>
<th>Control Leads</th>
<th>Comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean (ms)</td>
<td>Std. Dev.</td>
</tr>
<tr>
<td>Implant (PSA)</td>
<td>280</td>
<td>0.11</td>
<td>0.12</td>
</tr>
<tr>
<td>2 weeks</td>
<td>273</td>
<td>0.09</td>
<td>0.07</td>
</tr>
<tr>
<td>4 weeks</td>
<td>262</td>
<td>0.10</td>
<td>0.15</td>
</tr>
<tr>
<td>6 weeks</td>
<td>268</td>
<td>0.10</td>
<td>0.15</td>
</tr>
<tr>
<td>3 months</td>
<td>252</td>
<td>0.09</td>
<td>0.08</td>
</tr>
</tbody>
</table>

Statistical significance is defined as $p \leq 0.05$. t-test

Table 6. Patient information and principal safety results, polyurethane ThinLine II Sterox clinical study (All test leads, 238 patients)

<table>
<thead>
<tr>
<th>Total</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Patients</td>
<td>238</td>
</tr>
<tr>
<td></td>
<td>Devices*</td>
<td>461</td>
</tr>
<tr>
<td></td>
<td>Device Exposure, Months</td>
<td>3276</td>
</tr>
<tr>
<td></td>
<td>Duration, Mean ± SD, (Range), Months</td>
<td>7.5 ± 2.3 (0.1-12.5)</td>
</tr>
<tr>
<td></td>
<td>Patient age per implant, Mean ± SD, (Range), Years</td>
<td>73.0 ± 13.0 (15-96)</td>
</tr>
<tr>
<td></td>
<td>Sex, Female, Number, %</td>
<td>105, 44%</td>
</tr>
<tr>
<td></td>
<td>Clinical Complications, Number, Event Rate %</td>
<td>6, 0.16%</td>
</tr>
<tr>
<td></td>
<td>Clinical Observations, Number, Event Rate %</td>
<td>30, 0.92%</td>
</tr>
</tbody>
</table>

*Some patients implanted with multiple leads.

Results
Table 5 provides a comparison of pacing thresholds for Objective 1, study lead model 430-35S, 432-35S, and 438-35S as compared to control model 430-10, 432-04, and 438-10.

For Objective 2, model 430-35S electrical performance was equivalent to a commercially available steroid-eluting passive fixation lead.

Table 6 shows summary patient information and principal safety results for the polyurethane ThinLine II Sterox leads.
IMPLANT INFORMATION

NOTE: Refer to the appropriate ImageReady MR Conditional Pacing System or Defibrillation System MRI Technical Guide for considerations affecting choice and implant of leads for use as part of an MR Conditional system.

Proper surgical procedures and techniques are the responsibility of the medical professional. The described implant procedures are furnished for informational purposes only. Each physician must apply the information in these instructions according to professional medical training and experience.

Precautions

- Remove the stylet and stylet guide/cap before connecting the lead to the pulse generator. Leaving the stylet in the lead could cause coil fracture and/or heart perforation.
- Do not suture directly to the insulation. Always use the suture sleeve to anchor the lead.

Sterilization

This product is supplied in a sterile package for direct introduction into the operating field. The package and its contents have been exposed to ethylene oxide gas, and sterility is verified on each lot. Before the package is opened, it should be examined carefully for damage that may have compromised sterility. (For instructions on opening the sterile package, see Figures 1 and 2.) If such damage is detected, the entire contents should be returned to Boston Scientific.

Storage

Store at 25°C (77°F). Excursions permitted between 15°C to 30°C (59°F to 86°F). Transportation spikes permitted up to 50°C (122°F).

Handling

The conductor or its insulating material may be damaged if stretched, crimped, or crushed. Avoid subjecting the lead to these or other unusual stresses.

The lead’s insulating material has an electrostatic affinity for particulate matter and thus should not be exposed to lint, dust, or other similar contaminants.

Precautions

- Avoid the use of excessive force or surgical instruments, as damage to the insulation could cause leakage and/or prevent proper lead function.
- Do not wipe or immerse the electrode in fluid.
- Use the suture sleeve when securing the lead to avoid placing the lead under extreme tension.
- Avoid bending the conductor coil, since attempts to restore the original shape may weaken the structure.

General Information

It is important to position the lead so as to minimize mechanical stresses and maximize electrical contact with the cardiac wall. Implantation should, therefore, be performed in a facility permitting fluoroscopic verification of satisfactory lead tip placement.

Available transvenous implantation routes include the cephalic, subclavian and external or internal jugular veins. Venous access can be gained by employing either the venipuncture (suitable for the subclavian or internal jugular routes) or cutdown (suitable for the cephalic or external jugular routes) techniques.

If the subclavian route is selected and access by venipuncture is preferred, a percutaneous lead introducer (7 French or larger) should be used, and its application should be guided by the following considerations:

Precautions

- The subclavian venipuncture technique for lead introduction may be associated with an increased risk of conductor failure due to compressive forces generated in the medial angle between the clavicle and the first rib; thus, an extremely medial introduction site should be avoided.

Insertion Procedures

To employ the cutdown technique, expose and incise the desired vein. For the venipuncture technique, insert a lead-introducer sheath into the desired vein (see instruction sheet packaged with introducer).
Under fluoroscopic observation and with a straight stylet fully inserted into the lead, either introduce the lead into the incised vein (for cutdown), or advance the lead through the lead-introducer sheath and into the desired vein (see Figure 3). If desired, the vein pick included in the sterile package may be used to facilitate lead introduction (see Figure 4) when employing the cutdown technique.

Cautiously advance the lead. If resistance is encountered, withdraw the lead a short distance and then readvance it. Repeat this procedure until the lead tip enters the right atrium. The tip of an atrial or ventricular lead can be advanced to the desired stimulation site by following one of the two procedures below:

**Atrial Placement**
1. After advancing the lead tip into the right atrium, partially withdraw the stylet so that the lead’s distal end begins resuming its J shape and points anteromedially.
2. Maintaining fluoroscopic observation, advance the lead tip while holding the stylet stationary until the tip enters and becomes lodged in the atrial appendage.
3. If the lead tip is properly lodged in the appendage, the lead’s J curve will straighten slightly when the lead is gently retracted a short distance. Under AP fluoroscopy, the lead tip should point medially toward the left atrium and should sway from side to side with each atrial contraction.

**Ventricular Placement**
1. After advancing the lead tip into the right atrium, replace the straight stylet with one that has been slightly curved at the distal end. (Curve the stylet as shown in Figure 5.) The curve will assist in passing the lead across the tricuspid valve into the ventricle.
2. Once the lead has entered the ventricle, the straight stylet should be used again to cautiously advance the lead until the tip is lodged in the trabeculae at the apex. Be careful not to perforate the ventricular wall.
3. Verify with lateral fluoroscopy that the lead tip is not in a posterior position, which would probably indicate that it has entered the coronary sinus and must be repositioned.

**Threshold Measurements**
A pacemaker system analyzer is recommended for measuring the stimulation threshold and the appropriate sensing signal amplitude. During this procedure, the stylet should be withdrawn. The lowest possible pacing threshold should be sought.

**Ventricular**
Using a 500 Ω load, an acute stimulation threshold below 0.6 V or 1.2 mA can usually be obtained. However, maintaining the same resistance, it should not exceed 1.0 V or 2.0 mA. For satisfactory sensing, the ventricular sensing signal amplitude should be at least 5.0 mV. The recommended impedance range is 200-2000 Ω.

**Atrial**
Acute stimulation thresholds are usually lower than 1.0 V or 2.0 mA with a 500 Ω load. Acute atrial thresholds above 1.5 V or 3.0 mA (using a 500 Ω load) suggest a need to reposition the lead. The atrial sensing signal amplitude will typically range from 0.5 to 4.0 mV, but a value of 1.5 mV or above is preferable. The recommended impedance range is 200-2000 Ω.

**CAUTION:** Be sure that the stylet has been removed before connecting the lead to the implanted pulse generator. Leaving the stylet in the lead could cause coil fracture and/or heart perforation. Also be sure that any stylet guide/cap installed over the lead connector(s) (as a guide for the stylet and to maintain lubrication of the connector) has been removed.

**Securing the Lead**
Once electrode stability and a satisfactory stimulation threshold have been attained, slide the pre-installed suture sleeve into position at the desired anchor point. Secure the sleeve to the lead by tying a non-absorbable suture around the sleeve near its middle (see Figure 6). Pass an end of the same suture through subcutaneous tissue and, once again, tie it around the sleeve.
NOTE:

- The suture should be tied tight enough to prevent the lead from moving within the sleeve, but not so tight that it might deform the lead’s conductor coil.
- Do not tie the suture directly to the lead body.

1. Peel back the cover from the outer tray. Using the folded corner flap, remove the sterile inner tray (Figure 1).

2. Peel the lid from the inner tray to present the lead and accessories (Figure 2).

3. Advance the lead through the sheath of a percutaneous introducer and into the vein (Figure 3).

4. The vein pick may be used to lift and dilate the incised vein for introducing the lead (Figure 4).

5. Impart a gentle curve to the stylet by drawing it through a gloved hand or across a smooth, sterile instrument (Figure 5).
6. Slide the integral suture sleeve into the desired anchor position, and secure with a nonabsorbable suture (Figure 6).

POSTIMPLANT
Perform follow-up evaluation as recommended in the applicable pulse generator physician’s manual.

RETURNING EXPLANTED PRODUCTS
NOTE: Return all explanted pulse generators and leads to Boston Scientific. Examination of explanted leads can provide information for continued improvement in system reliability and warranty considerations.

NOTE: Disposal of explanted pulse generators and/or leads is subject to applicable laws and regulations. For a Returned Product Kit, contact Boston Scientific using the information on the back cover.
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image" alt="Symbol" /></td>
<td>Opening instructions</td>
</tr>
<tr>
<td><img src="image" alt="Symbol" /></td>
<td>Do not reuse</td>
</tr>
<tr>
<td><img src="image" alt="Symbol" /></td>
<td>Consult instructions for use on this website: <a href="http://www.bostonscientific-elabeling.com">www.bostonscientific-elabeling.com</a></td>
</tr>
<tr>
<td><img src="image" alt="Symbol" /></td>
<td>Do not resterilize</td>
</tr>
<tr>
<td><img src="image" alt="Symbol" /></td>
<td>Sterilized using ethylene oxide</td>
</tr>
<tr>
<td><img src="image" alt="Symbol" /></td>
<td>Use by</td>
</tr>
<tr>
<td><img src="image" alt="Symbol" /></td>
<td>Date of manufacture</td>
</tr>
<tr>
<td><img src="image" alt="Symbol" /></td>
<td>Lot number</td>
</tr>
<tr>
<td><img src="image" alt="Symbol" /></td>
<td>Serial number</td>
</tr>
<tr>
<td><img src="image" alt="Symbol" /></td>
<td>Do not use if package is damaged</td>
</tr>
<tr>
<td><img src="image" alt="Symbol" /></td>
<td>Manufacturer</td>
</tr>
<tr>
<td><img src="image" alt="Symbol" /></td>
<td>MR Conditional</td>
</tr>
</tbody>
</table>
## SPECIFICATIONS

<table>
<thead>
<tr>
<th></th>
<th>4456/4457 (Ventricular)</th>
<th>4458/4459 (Ventricular)</th>
<th>4479/4480 (Atrial)</th>
<th>4458/4459 (Ventricular)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Polarity</strong></td>
<td>Bipolar</td>
<td>Bipolar</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Distal Assembly</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Introducer size/insertion diameter (minimum)</td>
<td>7 Fr/2.3 mm (1 lead)</td>
<td>7 Fr/2.3 mm (1 lead)</td>
<td>10 Fr/3.3 mm (2 leads)</td>
<td>10 Fr/3.3 mm (2 leads)</td>
</tr>
<tr>
<td>The material</td>
<td>Silicone rubber</td>
<td>Silicone rubber</td>
<td>Silicone rubber</td>
<td>Silicone rubber</td>
</tr>
<tr>
<td>Eluting Collar</td>
<td>Silicone rubber</td>
<td>Silicone rubber</td>
<td>Silicon rubber</td>
<td>Silicon rubber</td>
</tr>
<tr>
<td>Steroid</td>
<td>Dexamethasone acetate (0.75 mg)</td>
<td>Dexamethasone acetate (0.75 mg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Electrode(s)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tip (cathode)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shape</td>
<td>Slotted/blunt</td>
<td>Slotted/blunt</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diameter</td>
<td>1.9 mm (5.7 French)</td>
<td>1.9 mm (5.7 French)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surface area</td>
<td>5 mm²</td>
<td>5 mm²</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Materials</td>
<td>IROX (Iridium oxide coated titanium)</td>
<td>IROX (Iridium oxide coated titanium)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coating (soluble)³</td>
<td>Polyethylene glycol</td>
<td>Polyethylene glycol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sleeve (anode)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surface area</td>
<td>31 mm²</td>
<td>33 mm²</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Materials</td>
<td>Platinum iridium</td>
<td>Platinum iridium</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Separation between electrodes</td>
<td>16 mm</td>
<td>16 mm</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Lead Body</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conductor construction</td>
<td>Parallel-wound bifilar coil</td>
<td>Parallel-wound bifilar coil</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conductor material</td>
<td>Nickel-cobalt alloy with silver core</td>
<td>Nickel-cobalt alloy with silver core</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conductor wire insulation</td>
<td>Polymer material</td>
<td>Polymer material</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insulation</td>
<td>55D polyurethane</td>
<td>80A silicone rubber</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Length</td>
<td>4456: 52 cm</td>
<td>4458: 52 cm</td>
<td>4479: 58 cm</td>
<td>4459: 58 cm</td>
</tr>
<tr>
<td></td>
<td>4479: 45 cm</td>
<td>4480: 52 cm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diameter</td>
<td>1.7 mm (5 French)</td>
<td>2 mm (6 French)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Resistance</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>To tip</td>
<td>40 Ω maximum</td>
<td>40 Ω maximum</td>
<td></td>
<td></td>
</tr>
<tr>
<td>To sleeve</td>
<td>40 Ω maximum</td>
<td>40 Ω maximum</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Connector Assembly</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diameter</td>
<td>3.2 mm (IS-1²)</td>
<td>3.2 mm (IS-1²)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Materials</td>
<td>Silicone rubber, 316L stainless steel</td>
<td>Silicone rubber, 316L stainless steel</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retention Strength³</td>
<td>10 N</td>
<td>10 N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Connector pin diameters</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cathode</td>
<td>1.6 mm</td>
<td>1.6 mm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anode</td>
<td>2.7 mm</td>
<td>2.7 mm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Connector pin length</td>
<td>5 mm</td>
<td>5 mm</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Accessories included</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stylets</td>
<td></td>
<td></td>
<td>Stylets</td>
<td></td>
</tr>
<tr>
<td>Stylet guide</td>
<td></td>
<td></td>
<td>Stylet guide</td>
<td></td>
</tr>
<tr>
<td>Vein pick</td>
<td></td>
<td></td>
<td>Vein pick</td>
<td></td>
</tr>
</tbody>
</table>

a. The tip electrode is encapsulated in polyethylene glycol (PEG), which is intended to maintain the cleanliness of the electrode during the packaging process.
b. IS-1 refers to the international standard ISO 5841-3:2013.